Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anaemia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anaemia
    FDA Approves Ferumoxytol for Iron Deficiency Anaemia in Patients With CKD - (DGNews)
    TopAbstracts in Anaemia 06/24/2009 - (DGNews)
    TopAbstracts in Anaemia 06/10/2009 - (DGNews)
    Use of Mycophenolate Mofetil Associated With Pure Red Cell Aplasia, Warns Health Canada - (DGNews)
    Once-Monthly Continuous Erythropoietin Receptor Activator Safe Switch for Managing Anaemia in Renal Transplant Patients Taking Erythropoiesis Stimulating Agents: Presented at ATC - (DGDispatch)

    News archive

     Recent webcasts/CME - Anaemia
    Assuring the Safe and Appropriate Management of Anemia in Two Patient Populations: Cancer and Chronic Kidney Disease
    Anemia Following Roux-en-Y Surgery for Morbid Obesity: A Review

    Webcasts/CME archive

     Recent cases - Anaemia
      Laryngeal Manifestations of Haemochromatosis
      Acute Myocardial Infarction and Pulmonary Embolism in a Young Man with Pernicious Anemia-Induced Severe Hyperhomocysteinemia
      Hook Worm Caused Chronic Anemia Found During the Procedure of Acute Gastrointestinal Bleeding: A Case Report
      Idiopathic Autoimmune Hemolytic Anemia Due to Lecithin Overdose: A Case Report
      The First Description of Severe Anemia Associated with Acute Kidney Injury and Adult Minimal Change Disease: A Case Report

      Cases archive
        




      my personal edition > anaemia > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Immunological Safety Not a Problem with Bovine-Derived Human Blood Substitute: Presented at AAAAI

      By Jill Stein

      DENVER, CO -- March 10, 2003 -- Researchers report that the risk of systemic immunoglobulin E (IgE)-mediated reactions is negligible in patients receiving the bovine-derived human blood substitute Hemopure.

      Hemopure is a an investigational product that is being developed as a treatment for the signs and symptoms of acute anaemia in adults undergoing orthopaedic surgery to eliminate reduce the need for red blood cell transfusions in these patients.

      Dr. Maria Gawryl, with Biopure Corporation in Cambridge, Massachusetts, United States, and co-workers at Johns Hopkins University in Baltimore, Maryland, evaluated IgE and IgG immune responses in patients receiving multiple doses of Hemopure in clinical trials.

      Dr. Gawryl presented the data here March 9th at the 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.

      His research team collected blood samples from patients treated with Hemopure and controls before and 4 to 6 weeks after treatment. Hemopure was administered in single or divided doses up to 300 g hemoglobin (2.5 L).

      Results showed that Hemopure-specific IgG responses were detected in 54% of Hemopure-treated patients and 4.3% of control patients. Positive IgG antibody responses in control patients occurred at low frequency and concentration (range 2:1-16.8 kAU/mL) and may reflect either non-specific binding or cross-reacting antibodies.

      In 497 Hemopure-treated and 416 control patients -- including patients who were infused multiple times over several weeks -- only one patient treated with Hemopure developed Hemopure-specific IgE antibodies 6 weeks after treatment (4.6 fold greater than negative control serum binding). Importantly, there were no serious adverse events reported in this patient. Non-serious events included an elevated temperature and itching in the perineal area.

      One control patient and five Hemopure patients had IgE antibody responses designated as equivocal (less than 3 fold negative control serum binding). This IgE antibody level was too low to permit competitive soluble antigen inhibition for specificity confirmation, and it was not considered significant.

      Dr. Gawryl said the results provide evidence that Hemopure is well tolerated in various clinical settings at a variety of doses and support its use as a red blood cell replacement in the surgical setting. Clinical experience in South Africa, where the solution is approved for surgical use, supports this conclusion, he said.

      The study was sponsored by Biopure Corporation in Cambridge, Massachusetts.


      [Study title: Immunologic Safety Studies of Bovine-Derived Human Blood Substitute (Hemopure). Abstract 390]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send